Work

ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps6092

Authors: Ezra E.W. Cohen, Ranee Mehra, Amanda Psyrri, Julie E. Bauman, Richard Schaub, Li Zhou, Li Li, Vijayvel Jayaprakash, Joel Guigay

Institutions: University of California San Diego, Johns Hopkins Hospital, National and Kapodistrian University of Athens, University General Hospital Attikon, University of Arizona, Incyte (United States), Bristol-Myers Squibb (United States), Centre Antoine Lacassagne

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889984963

Cites:

Cited by: 3

Related to: 10